BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Firms Flock to Epic's CTC Platform


8/15/2012 7:58:47 AM

SAN DIEGO--(BUSINESS WIRE)-- Epic Sciences, Inc. (“Epic”), a privately held cancer diagnostics company, announced today that it has established collaborations with six pharmaceutical partners employing Epic’s proprietary Circulating Tumor Cell (“CTC”) technology. The partners include two of the top four pharmaceutical companies worldwide. In total, the collaborations include 12 clinical trials involving over 40 distinct projects measuring 18 different protein or genomic tumor markers on CTCs. The clinical trials include sites in the US, Europe and Asia with over 1500 patients and 2500 clinical samples in prostate, lung, breast, pancreatic and ovarian cancers.

These partnerships leverage Epic’s unique platform to identify and characterize rare cells in fluids. Most CTC technologies employ a physical enrichment strategy based on a few markers thought to be present on the majority of cancer cells. Because cancer cells are heterogeneous, Epic chose a different path which physically retains all of the cells and identifies the CTCs using multi-parametric analysis in a “…no cells left behind” strategy.

“Given that we have been operating in stealth mode, Epic has been pleased by the extraordinary level of interest and clinical deal flow around our CTC detection and characterization platform,” said Dr. David Nelson, President and CEO of Epic Sciences.

“These collaborations with leading pharmaceutical companies provide a strong and diverse basis for Epic’s companion diagnostic pipeline,” said Nelson. “By using Epic to molecularly characterize CTCs, our pharmaceutical partners are looking to improve the success rate, decrease the cost, and expedite commercial launch of their targeted therapies. Payers are also expected to gain by achieving better health economics as care evolves to provide the right drug to the right patient at the right time. Ultimately, of course, we hope that the biggest beneficiaries will be all of the patients whose individual outcomes are improved by personalized medicine guided by Epic’s diagnostic products.”

About Epic Sciences

Epic Sciences, Inc. (www.epicsciences.com) is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells (“CTCs”). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Contact:

Epic Sciences, Inc.

David Nelson, 858-356-6611

cdx@epicsciences.com




 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES